Cassava Sciences Inc vs Seagate Technology Holdings PLC — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Seagate Technology Holdings PLC trades at $779.8 (market cap $176.19B). The key difference: Seagate Technology Holdings PLC is far larger — about 4471.8× Cassava Sciences Inc's market cap, and Seagate Technology Holdings PLC pays a 0.38% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Seagate Technology Holdings PLC for 41 Days on average.
| FLNA | STX | |
|---|---|---|
Market Cap | $39.40M | $176.19B |
Volume | 759,018 | 5,061,875 |
Sector | Health | Technology |
52-Week High | $4.64 | $1.09K |
52-Week Low | $0.68 | $211.63 |
Typical Hold Time | 37 Days | 41 Days |
Enterprise Value | -$43.28M | $178.34B |
Dividend Yield | — | 0.38% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Seagate Technology (STX) trades at $807.34, up 0.21% with bearish technical signals despite strong fundamental performance. The company reported Q2 2026 EPS of $5.71, beating estimates by 12%, and maintains robust profitability with 26.11% net margins. Recent news highlights competitive pressures as Toshiba plans to expand AI storage production, potentially challenging Seagate's pricing power in the high-capacity drive market.
While analyst consensus remains bullish with a $1,130 price target, near-term risks include increased competition and volatile cash flows. The stock's elevated valuation ratios (P/E 58.1, P/S 15.16) require sustained earnings growth justification, particularly as technical indicators signal caution with resistance at $816.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →